Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-12

Study Completion Date

2022-09-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open label, placebo-controlled, parallel design, single center, prospective study. Subjects will receive treatment with VKA. Subjects who reach the targeted INR, will receive single dose of Cofact. Multiple coagulation laboratory tests will be evaluated over a period of 15 days

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal

NCT01159210

Prothrombin Complex Factor Deficiency

COMPLETED PHASE4

Patient Convenience Study

NCT02597920

Atrial Fibrillation

COMPLETED

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

NCT04660747

Cerebral Venous Thrombosis

RECRUITING

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570

Embolism and Thrombosis Embolism Vascular Diseases +4 more

COMPLETED

Anticoagulant Clinics and Vitamin K Antagonists

NCT00966290

Blood Coagulation Disorders

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

* Male or female of nonchildbearing potential.
* Healthy subjects.

Exclusion Criteria

* Evidence of coagulation disturbances, or disposition for thrombo-embolic events
* Liver function tests more than 1.2 times the upper normal limits
* Participants with thyroid disorders as evidenced by assessment of TSH levels outside the normal reference range at screening.
* Prior history of thromboembolic complications including those in first degree relatives.
* Glomerular filtration rate (GFR) is lower than estimated GFR 62 mL/min/1.73 m2 using the Modification of Diet in Renal Disease Study equation.
* Anaphylactic or systemic reactions to human plasma, plasma products, or blood products.
* History of hypersensitivity to active or inactive excipients of VKA
* Gastrointestinal disease that may impair VKA absorption..
* Participation in another clinical study \<30 days prior to study entry.
* Any clinically significant history of or current clinically significant disease or disorder as judged by the Investigator.
* Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -11 or Day -1.
* Positive pregnancy test at screening, Day -11, or Day -1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes